Replay available

Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) Q2 2026 earnings conference call, held 2026-08-11. Replay captured from the company's public earnings webcast.

Tue, August 11, 2026 at 4:30 PMendedReplay
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Dan Ferry

Host, LifeSci Advisors

Jon Congleton

Chief Executive Officer, Mineralis Therapeutics

Eric Warren

Chief Commercial Officer, Mineralis Therapeutics

Adam Levy

Chief Financial Officer, Mineralis Therapeutics

Richard Law

Analyst, Goldman Sachs

Michael DeFiore

Analyst, Evercore ISI

Jason Gerberry

Analyst, Bank of America

Evan Lang

Analyst, Guggenheim Securities (for Seamus Fernandez)

Mohit Bansal

Analyst, Wells Fargo

Rami Kasuda

Analyst, LifeSci Capital

Tara Bancroft

Analyst, TD Cowen

Matthew Caulfield

Analyst, HC Wainwright

Dennis Ding

Analyst, Jefferies

Replay transcript excerpt

Welcome to the Mineralis Therapeutics second quarter 2026 conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. Should anyone require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry of LifeSci Advisors. Please go ahead, sir. Thank you. I would like to welcome everyone joining us today for our second quarter 2026 conference call. This afternoon, after the close of market trading, we issued a press release providing our second quarter 2026 financial results and business updates. A replay of today's call will be available on the investor section of our website approximately one hour after its completion. After our prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings, including our annual report on Form 10-K and subsequent filings. Please note that these forward-looking statements reflect our opinions only as of today, August 11, 2026. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. I would now like to turn the call over to Jon Congleton, Chief Executive Officer of Mineralis T...

More from Mineralys Therapeutics, Inc.